Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Illegal online pharmacies: How endemic are they?
  2. AstraZeneca to stockpile medicines in preparation for no-deal Brexit
  3. FDA grants orphan drug designation to Asceneuron’s ASN120290
  4. UK Government loses vote on EMA amendment to Brexit bill
  5. EC grants Akcea and Ionis’s inotersen marketing authorisation

Latest Content

FDA approves expanded indication for Novartis drug Kisqali

Novartis has obtained approval from the US Food and Drug Administration (FDA) for its Kisqali (ribociclib) to treat advanced or metastatic breast cancer patients who are hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-).

EC grants Akcea and Ionis’s inotersen marketing authorisation

Ionis Pharmaceuticals and its affiliate Akcea Therapeutics have announced their drug Tegsedi (inotersen) has received marketing authorisation approval from the European Commission (EC) to treat stage one and two polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR amyloidosis).

Post-Curing on the Reduction of Cyclosiloxanes Contaminates

Drug manufacturers are increasingly concerned about the sources of potential contamination from processing equipment. To give a sense of the scale of this problem, 15% of drug recalls reported by the US Food and Drug Administration (FDA) in the last six months were due to contamination from processing equipment. 

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top